Jack SmithMarch 19, 2018
AXIM Biotechnologies (AXIM) reported fiscal 2017 full-year results, with CEO Dr. George Anastassov highlighting “solid progress” the company is making on its clinical pipeline, including it getting a mass-market chewing gum to help cancer patients with nausea and vomiting. The company said it ended the year with $2.1 million in cash, losing 8 cents a share, […]